Adocia SA
PAR:ADOC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Adocia SA
PAR:ADOC
|
FR |
|
Fulton Financial Corp
NASDAQ:FULT
|
US |
|
S
|
Suzhou K-Hiragawa Electronic Technology Co Ltd
SSE:603052
|
CN |
|
POCO Holding Co Ltd
SZSE:300811
|
CN |
|
Azure Power Global Ltd
OTC:AZREF
|
IN |
|
L
|
Labiana Health SA
MAD:LAB
|
ES |
|
A
|
ADTechnology Co Ltd
KOSDAQ:200710
|
KR |
|
Fidelity D&D Bancorp Inc
NASDAQ:FDBC
|
US |
|
G
|
Guoan International Ltd
HKEX:143
|
HK |
Adocia SA
Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2012-02-20. The firm specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.
Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2012-02-20. The firm specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.
